The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium glucose co-transporter-2 inhibitors (SGLT2i), and statin-based regimens. RASi and SGLT2i reduce risk of CKD progression irrespective of primary cause of kidney disease, suggesting they target final common pathways. Targeting aldosterone overactivity with a nonsteroidal mineralocorticoid receptor antagonist (MRA) also reduces cardiorenal risk in patients with albuminuric diabetic kidney disease already treated with RASi.

In adults with BMI ≥27 kg/m and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA level.

Lingvay I, Deanfield J, Kahn SE, et al; SELECT Trial Investigators. Diabetes Care. 2024;47:1360-1369.

In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.

Usman MS, Bhatt DL, Hameed I, et al. Lancet Diabetes Endocrinol. 2024;12:447-461.

Alcohol and mortality in Mexico: prospective study of 150 000 adults.

Background: Alcohol consumption is a leading cause of premature death globally, but there is no large-scale prospective evidence from Mexico.

Methods: The Mexico City Prospective Study recruited 150 000 adults aged 35 years or older between 1998 and 2004. Participants were followed up until Oct 1, 2022 for cause-specific mortality.